We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sleeping Pills May Claim Half a Million Lives Annually

By HospiMedica International staff writers
Posted on 15 Mar 2012
The use of hypnotic sleep aids is associated with a three- to five-fold higher mortality risk when compared with the risk for nonusers, according to a new study. More...


Researchers at the Scripps Clinic (La Jolla, CA, USA) reviewed electronic medical records (EMRs) and conducted a one-to-two matched cohort survival analysis of 10,529 patients (mean age 54 years) who received hypnotic prescriptions and 23,676 matched controls with no hypnotic prescriptions. The participants were followed for an average of two and a half years, between January 2002 and January 2007. The main outcome measures were Hazard ratios (HRs) for death, adjusted for age, gender, smoking, body mass index (BMI), ethnicity, marital status, alcohol use, and prior cancer.

The results showed that overall 6.1% of hypnotic users died during observation, compared with 1.2% of the nonusers. For groups prescribed 0.4–18, 18–132, and over 132 doses per year, the HRs were 3.60, 4.43, and 5.32, respectively, demonstrating a dose–response association. Separate analyses for several common benzodiazepine hypnotics, barbiturates, and sedative antihistamines also demonstrated elevated HRs. Hypnotic use in the upper tercile was also associated with a significant elevation of incident cancer, with a HR of 1.35. The results were robust within each comorbidity group, indicating that the associations were not attributable to preexisting disease. The study was published on February 27, 2012, in BMJ Open.

“We cannot be certain what portion of the mortality associated with hypnotics may have been attributable to these drugs, but the consistency of our estimates across a spectrum of health and disease suggests that the mortality effect of hypnotics was substantial,” said lead author Daniel Kripke, MD. “Rough order-of-magnitude estimates ... suggest that in 2010, hypnotics may have been associated with 320,000 to 507,000 excess deaths in the US alone.”

More than two dozen studies have examined the mortality risk associated with hypnotics use, and two-thirds of them demonstrated significant associations. The first was conducted more than 30 years ago, which showed that both cigarette smoking and hypnotic use were associated with excess mortality; however, the link to hypnotics was largely discounted because the study was not designed primarily to examine these drugs.

Related Links:

Scripps Clinic



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.